Circulating tumor DNA indicates increased risk of relapse after stem cell transplant in patients with diffuse large B-cell lymphoma

Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists suggests that patients whose blood or stem cell samples harbor tumor DNA are likely to relapse.

Read more

Venetoclax added to standard treatments shows promise in high-risk myeloid blood cancers

The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.

Read more

CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

Read more

Study reveals surprising benefit of clonal hematopoiesis in allogeneic transplants

Clonal hematopoiesis (CH) is a recently identified condition in which mutations associated with blood cancers are detected in the blood of some healthy, usually older, individuals who don’t have cancer. People with CH, while asymptomatic, have an elevated risk of developing blood cancers and other negative health outcomes, including heart attacks and strokes.

Read more

Donor stem cell transplant shown to improve survival in older patients with myelodysplastic syndrome

A new clinical trial offers the most compelling evidence to date that a donor stem cell transplant can improve survival rates for older patients with higher-risk myelodysplastic syndrome (MDS), Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

Read more

Dana-Farber to present more than 40 research studies at 2020 ASH Annual Meeting

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology (ASH) Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.

Read more

Fred Hutch at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots — and more

SEATTLE — Nov. 18, 2020 — Fred Hutchinson Cancer Research Center’s latest findings on cell therapies, repairing immune function, and more will be featured at the 62nd American Society of Hematology Annual Meeting & Exposition, to be held virtually Dec. 5 – 8.Dr. Stephanie Lee, ASH president and Fred Hutch physician-scientist will kick off the meeting with a fireside chat with Dr.

Read more

New Mayo Clinic studies to be presented at American Society of Hematology meeting

Mayo Clinic researchers will present findings at the American Society of Hematology Annual Meeting Dec. 7–10 in Orlando.
New Mayo Clinic studies to be presented include:
DNA analysis identifies elevated risk factor for myeloma in individuals of African ancestry
Study identifies more precise assessment measures for patients newly diagnosed with chronic lymphocytic leukemia
Researchers develop method to assess cancer-fighting cell therapy’s effectiveness

Read more

Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds

A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma.

Read more

Dana-Farber scientists present promising findings in multiple myeloma at ASH Annual Meeting

Results of studies on a novel agent to treat multiple myeloma and a combination therapy aimed at slowing the progression of a precursor myeloma condition are among reports being presented by Dana-Farber Cancer Institute investigators at the ASH Annual Meeting.

Read more

Use of venetoclax in reduced-intensity transplant conditioning regimen in patients with high-risk myeloid cancers shows promise in early trial

For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients’ bodies, a study led by Dana-Farber Cancer Institute researchers suggests.

Read more